Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
Sentiments toward Japan’s FY2026 drug pricing reform have deteriorated sharply among pharmaceutical companies, with around 60% of respondents expressing dissatisfaction, according to a survey conducted by Jiho. Of the 60 companies that responded, 23.3% (14 firms) said they were “very…
To read the full story
Related Article
- A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
March 24, 2026
- PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
- Half of Drug Makers Reluctantly Support G1 Rule Overhaul: Jiho Survey
March 12, 2026
- Minimum Price Hike, Spillover Abolition Win Industry Support in FY2026 Reform: Jiho Poll
March 10, 2026
- Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
- Majority of Drug Makers “Somewhat Satisfied” with FY2024 Revision: Poll
March 7, 2024
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…